Literature DB >> 25091209

The -1082A>G polymorphism in promoter region of interleukin-10 and risk of digestive cancer: a meta-analysis.

Chunxue Li1, Weidong Tong1, Baohua Liu1, Anping Zhang1, Fan Li1.   

Abstract

The -1082A>G polymorphism is located in promoter region of interleukin-10 (IL-10) and it could affect the production of IL-10. Numerous studies have investigated the association between IL-10 -1082A>G and risk of digestive cancer. However, the conclusion is still inconsistent. Here, we have performed a meta-analysis and systematic review to determine the association between the IL-10 -1082A>G and susceptibility to digestive cancer. In this meta-analysis, we identified 40 eligible studies, involving 7195 patients of digestive cancer and 11755 controls. By pooling all eligible studies, we found the variant -1082G allele significantly increased risk of digestive cancer (G vs. A: OR = 1.181, 95% CI: 1.057-1.319). Further stratified analysis was performed to evaluate the influence of cancer types, ethnicities, study design, sample size and Hardy-Weinberg equilibrium. Stratified analysis suggested that, the -1082A>G polymorphism was only associated with increased risk for gastric cancer (G vs. A: OR = 1.281, 95% CI: 1.102-1.488) and in Asian population (G vs. A: OR = 1.399, 95% CI: 1.188-1.646). No significant publication bias was detected. Based on 40 studies and 18950 participants, we found the variant IL-10 -1082G allele significantly increased susceptibility to digestive cancer, especially for gastric cancer and in Asian population.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25091209      PMCID: PMC4121615          DOI: 10.1038/srep05335

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


Cytokines have been investigated for decades and many important cytokines are involved in human diseases, such as interleukin-1 and osteoarthritis12. In 1989, Mosmann and colleagues3 first reported a cytokine named “cytokine synthesis inhibiting factor (CISF)”, which was secreted by T helper 2 (Th2) clones and inhibited synthesis of interferon-γ (IFN-γ) in Th1 clones. The CISF is now known as interleukin-10 (IL-10). IL-10 is a cytokine with potent anti-inflammatory activity4, produced by macropahges, T helper 2 cells and B lymphocytes56. IL-10 is a multifunctional cytokine involved in both innate and adaptive immune response46. As an inflammatory cytokine, IL-10 participates in the development of various diseases, such as kidney disease7, heart failure8, chronic infection910 and cancer10. Although IL-10 has been extensively studied, the exact role of IL-10 in cancer is still elusive, since evidence suggested that IL-10 could mediate both anticancer immune response and immune-mediated rejection of cancer6. The gene encoding IL-10 is located on chromosome 1 (1q31-1q32). Three single nucleotide polymorphisms (SNPs) have been confirmed in the promoter region of IL-10: -592C>A (rs1800872), -819C>T (rs1800871), and -1082A>G (rs1800896). Previous studies have shown that the three polymorphisms could affect the expression of IL-101112 and alter the susceptibility to digestive cancers131415. In addition to the elusive role of IL-10 in cancer development, the relationship between functional polymorphisms in IL-10 promoter region and cancer risk is also mysterious. Several meta-analyses have been performed to evaluate the association between IL-10 polymorphisms and cancer risk1617; however, the association between -1082A>G polymorphism and digestive cancer has not been assessed. Thus, this meta-analysis was performed to investigate the association between 1082 polymorphism and digestive cancer and assess the influence of confounding factors.

Methods

Searching strategy

This meta-analysis were conducted and reported in corresponding to the PRISMA guidelines of systematic reviews and meta-analyses (see Supplementary Table S1 online)18. Online databases of PubMed, EMBASE, and CNKI were searched. The following terms were used: “Interleukin-10” or “IL10”, “polymorphisms, single nucleotide” or “SNPs” and “cancer” or “ neoplasm”. Both plain text and medical subheadings of above key words were used for searching. No limitation of origin, languages, or other items was placed. To identify additional studies, references of previous meta-analyses and reviews were also manually searched.

Inclusion criteria

Records identified from databases were first screened by titles and abstracts, and then full-text articles were further reviewed. Eligible studies were judged by the following criteria: (1) case-control studies; (2) investigating the association between IL-10 -1082A>G polymorphism and digestive cancer risk; (3) available genotype distribution data. According to the inclusion criteria, 2 authors (LC and TW) extracted eligible studies independently. The two authors reached consensus on each records.

Data extraction

Name of first author, year of publication, country where the study was carried out, cancer type, ethnicity, the source of control, number of cases and controls, genotype frequency in cases and controls were collected from eligible studies. Ethnicity was simply classified as Asian, Caucasian, and Latino (Table 1). Included studies were defined as hospital-based (HB) and population-based (PB) according to the source of control. Sample size of eligible studies was classified as large (>500) or small (<500). All data were extracted by two authors (LC and TW) independently with a predesigned data-collection form. Two authors reached consensus on each item.
Table 1

Baseline Characteristics of Eligible Studies

AuthorYearCancer TypeCountryEthnicityStudy DesignSample SizeCasesControlsHWE
Alpízar-Alpízar W2005GCCosta RicaLatinosPBSmall4544Y
Bai XL2008GCChinaAsiansHBSmall104111NA
Bouzgarrou N2009HCCTunisiaAfricanHBSmall58145Y
Cacev T2008CRCCroatiaCaucasianPBSmall160160N
Cozar JM2007CRCSpainCaucasianHBSmall96176Y
Crivello A2006CRCItalyCaucasianPBSmall62124Y
Crusius JB2008GCEuropeanCaucasianPBLarge2351134N
El-Omar EM(EC)2003ECUSAMixedPBSmall161210Y
El-Omar EM(GC)2003GCUSAMixedPBLarge314210Y
Forte GI2008GCItalyCaucasianHBSmall42185N
García-González MA2007GCSpainCaucasianPBLarge404404Y
Guo W (EC)2005ECChinaAsiansPBLarge203443N
Guo W (GC)2005GCChinaAsiansPBLarge152443N
He B2012GCChinaAsiansHBSmall196248Y
Heneghan MA2003HCCChinaAsiansHBSmall98175Y
Kamangar F2006GCFinlandCaucasianPBSmall112205Y
Kang JM2009GCKoreaAsiansHBLarge334335Y
Kim J2012GCKoreaAsiansHBLarge495495Y
Ko KP2009GCKoreaAsiansPBSmall80336Y
Lee JY2005GCKoreaAsiansHBSmall122120Y
Liu J2011GCChinaAsiansHBSmall234243N
Lu W2005GCChinaAsiansPBLarge250300N
Macarthur M2005CRCUKCaucasianPBLarge257408Y
Migita K2005HCCJapanAsiansHBSmall48188N
Morgan DR2006GCHondurasLatinosHBSmall170161Y
Nieters A2005HCCChinaAsiansHBSmall249250NA
Ognjanovic S2009HCCUSACaucasianPBSmall118230NA
Pan XF2013GCChinaAsiansHBLarge308308Y
Savage SA (EC)2004ECChinaAsiansHBLarge115385N
Savage SA (GC)2004GCChinaAsiansHBSmall84385N
Scola L2009PCItalyCaucasianPBSmall48131Y
Shin CM2011GCKoreaAsiansHBLarge632237Y
Shin HD2003HCCKoreaAsiansHBLarge230792Y
Sugimoto M2007GCJapanAsiansHBSmall104168Y
Wu MS2002GCChinaAsiansHBSmall150220Y
Xiao H2009GCChinaAsiansHBLarge220624Y
Yin YQ2012GCChinaAsiansHBSmall7575N
Zambon CF2005GCItalyCaucasianHBLarge129644Y
Zeng X2012GCChinaAsiansPBSmall151153N
Zhou Y2011GCChinaAsiansPBSmall150150N

CRC: Colorectal Cancer; EC: Esophageal Cancer; GC: Gastric Cancer; HCC: Hepatocellular Carcinoma; PC: Pancreatic Cancer; HB: hospital-based; PB: population-based; Large: >500 participants; Small: <500 participants; HWE: Hardy-Weinberg equilibrium; Y: agreement with HWE; N: disagreement with HWE; NA: unable to estimate.

Quality assessment

“Methodological quality assessment scale” (the scale can be found as Supplementary Table S2 online), a quality scale modified form previous meta-analyses19, was used to evaluate methodological quality of eligible studies. Briefly, the following items were assessed: the representativeness of cases, source of controls, ascertainment of relevant cancer, sample size, quality control of genotyping methods, and Hardy-Weinberg equilibrium (HWE). Quality scores ranged from 0 to 10 (0: the lowest; 10: the highest).

Statistical analysis

Odds ratios (ORs) with 95% confidence intervals (95% CIs) were calculated to estimate the association strength between IL-10 -1082A>G polymorphism and digestive cancer risk. Deviation from the Hardy–Weinberg equilibrium (HWE) among controls subjects was tested by a x2-test and a P<0.05 was considered as significant disequilibrium. The pooled ORs were calculated for allele comparison (G vs. A), homozygote comparison (GG vs. AA), heterozygote comparison (GA vs. AA), and dominant models (GG/GA vs. AA, considering the dominant effect of the IL-10 -1082G allele). For some studies only combined genotype (GG/G) data was reported2021, thus, only dominant comparison models were conducted for these studies. Heterogeneity between studies were determined by chi-square based on Q test and the random-effects model was used when there was significant heterogeneity (P<0.1); otherwise, the fixed-effects model was applied22. Sub-group analyses were conducted according to cancer types, ethnicities, source of control, HWE, and sample size. Sub-group analysis was not performed for those subgroups with less than 2 studies. When significant heterogeneity presented, meta-regression was performed to detect the source of heterogeneity. Egger's test and Begg's test were used to test publication bias, and a p < 0.05 was significant23. Sensitivity analysis was performed to assess individual studies' effect on the pooled results. All meta-analyses were calculated by STATA (version 10.0; Stata Corp, College Station, Texas USA). And all P values are two-side.

Results

Overview of eligible studies

According to our searching strategy, 752 records were retrieved and screened. After primary screening, 38 full-text papers were retrieved for further assessment1314152021242526272829303132333435363738394041424344454647484950515253545556. The study reported by Zhou SZ et al was excluded for lacking of detail genotype distribution data56. In the studies reported by El-Omar EM29, Guo W32, and Savage SA14, both gastric cancer and esophageal cancer were reported and the data were presented independently, and each kind of the cancer was treated as a separate study. Thus, 40 eligible studies were included in this meta-analysis13141520212425262728293031323334353637383940414243444546474849505152535455. The process of study selection was shown in Figure 1.
Figure 1

Flow Chart of Study Selection.

Both gastric cancer and esophageal cancer were reported in 3 studies, and each kind of cancer was treated as a separate study. Thus, 37 studies were included in qualitative synthesis and 40 studies were included in quantitative synthesis.

Of the 40 eligible studies, 7195 patients of digestive cancer and 11755 controls were enrolled. Baseline characteristics of those studies were shown in Table 1. Most studies were performed among Asian population (24 studies) and Caucasian population (11 studies). Methodological quality of eligible studies was assessed by a quality scale reported by previous studies. Generally, quality of eligible studies was acceptable, with an average score of 7.3. Of 40 analyzed studies, 23 were hospital-based and 17 studies were population based. As for HWE, 24 studies were in agreement with HWE, 13 studies were in disagreement with HWE and it was unable to test in 3 studies202144 due to combined data (Table 2). Since no genotyping error was reported, all studies were included in quantitative synthesis, and stratified analysis was performed to assess the influence of disagreement of HWE.
Table 2

Meta-analysis Results

 G vs. AGG vs. AAGA vs. AAGGGA vs. AA
 StudiesOR (95% CI)PheterStudiesOR (95% CI)PheterStudiesOR (95% CI)PheterStudiesOR (95% CI)Pheter
Overall371.181 (1.057–1.319)*<0.001331.305 (1.044–1.631) *<0.001371.168 (1.015–1.344) *<0.001401.153 (1.005–1.323) *<0.001
Cancer Types            
CRC40.937 (0.805–1.090)0.7140.873 (0.638–1.195)0.73740.914 (0.709–1.179)0.57240.903 (0.709–1.149)0.552
EC30.982 (0.820–1.175)0.59130.872 (0.559–1.361)0.86431.113 (0.850–1.456)0.76131.070 (0.825–1.387)0.656
GC251.281 (1.102–1.488) *<0.001221.575 (1.146–2.164) *<0.001251.277 (1.067–1.527) *<0.001261.275 (1.056–1.538) *<0.001
HCC41.104 (0.797–1.530)0.28331.355 (0.587–3.124)0.75741.022 (0.714–1.463)0.33560.912 (0.739–1.126)0.431
Ethnicity            
Asian221.399 (1.188–1.646) *<0.001192.072 (1.446–2.971) *0.068221.397 (1.161–1.680) *<0.001241.351 (1.108–1.649) *<0.001
Caucasian101.016 (0.930–1.111)0.796101.055 (0.880–1.264)0.649100.973 (0.786–1.205)0.044111.010 (0.881–1.159)0.386
Control Source            
PB161.151 (1.001–1.324) *<0.001151.336 (0.973–1.835)<0.001161.118 (0.915–1.364)0.001171.153 (0.964–1.379)0.001
HB211.212 (1.014–1.449) *<0.001181.246 (0.940–1.650)0.38211.216 (0.992–1.489)<0.001231.153 (0.935–1.422)<0.001
Sample Size            
Small221.151 (1.010–1.312) *0.016181.291 (1.010–1.649) *0.191221.170 (0.973–1.406)0.026251.109 (0.927–1.327)0.001
Large151.214 (1.013–1.456) *<0.001151.388 (0.944–2.040)<0.001151.164 (0.938–1.444)<0.001151.208 (0.974–1.498)<0.001
HWE            
YES241.125 (0.982–1.288)<0.001201.045 (0.871–1.253)0.412241.069 (0.896–1.275)<0.001241.103 (0.931–1.308)<0.001
NO131.280 (1.063–1.541) *<0.001131.553 (1.018–2.367) *<0.001131.386 (1.121–1.714) *0.04131.428 (1.151–1.772) *0.012

*Significant association; OR: odds ratio; CI: confident intervals; CRC: Colorectal Cancer; EC: Esophageal Cancer; GC: Gastric Cancer; HCC: Hepatocellular Carcinoma; HB: hospital-based; PB: population-based; Large: >500 participants; Small: <500 participants; HWE: Hardy-Weinberg equilibrium; YES: agreement with HWE; NO: disagreement with HWE.

Meta-analysis Results

By pooling all eligible studies, compared with the wild -1082A allele, we found the variant IL-10 -1082G allele was associated with significantly increased risk of digestive cancer in all four comparison models (G vs. A: OR = 1.181, 95% CI: 1.057–1.319; Heterogeneity, P<0.001; Figure 2 and Figure 3; Table 2).
Figure 2

Forest plot of IL-10 -1082A>G polymorphism and risk of digestive cancer, G vs. A.

Figure 3

Forest plot of IL-10 -1082A>G polymorphism and risk of digestive cancer, GGGA vs. AA.

Further sub-group analyses were conducted to assess the effects of potential confounding factors. When stratified by cancer types, we found the variant G allele only increased risk of gastric cancer (G vs. A: OR = 1.281, 95% CI: 1.102–1.488; Heterogeneity, P<0.001) but did not alter the risk of colorectal cancer (G vs. A: OR = 0.937, 95% CI: 0.805–1.090; Heterogeneity, P = 0.710), hepatocellular carcinoma (G vs. A: OR = 1.104, 95% CI: 0.797–1.530; Heterogeneity, P = 0.283) or esophageal cancer (G vs. A: OR = 0.982, 95% CI: 0.820–1.175; Heterogeneity, P = 0.591). As for ethnicities, significant association was only found among Asians (G vs. A: OR = 1.399, 95% CI: 1.188–1.646; Heterogeneity, P<0.001), while the -1082 polymorphism did not alter digestive cancer risk in Caucasians (G vs. A: OR = 1.016, 95% CI: 0.930–1.111; Heterogeneity, P = 0.796). HWE also significantly affected the pooled analysis. In the sub-groups classified according to source of control and sample size, meta-analysis results were quite consistent.

Heterogeneity and publication bias

Notably, significant heterogeneity was observed in most comparisons. Thus, meta-regression was performed to detect the source of heterogeneity. The results indicated that sample size (P<0.001), HWE (P<0.001), source of control (P<0.001), and cancer types (P = 0.03) contributed heterogeneity, while ethnicity (P = 0.207) did not. Publication bias was detected by Egger's test and Begg's test, and no evidence of publication bias was found (P = 0.133 for Begg's test and P = 0.524 for Egger's test; Figure 4). As shown in Figures 2,3,4, the study reported by Alpizar-Alpizar W24 was an outlier. Thus, sensitivity analysis was performed to assess individual study's effect by omitting one study each time. Sensitivity analysis revealed that the pooled results were not affected by the study by Alpizar-Alpizar W et al or any other studies (see supplementary Figure S3 online), indicating our results were stable and reliable.
Figure 4

Funnel plot of IL-10 -1082A>G polymorphism and risk of digestive cancer, G vs. A.

Circles represent the weight of studies.

Discussion

In this meta-analysis, we identified 40 eligible studies, including 7195 cases and 11755 controls. By pooling all eligible studies, we found the variant IL-10 -1082G allele significantly increased the susceptibility to digestive cancer, especially to gastric cancer and among Asian population. By pooling all eligible studies, we found the IL-10 -1082A>G polymorphism was associated with significantly increased risk of digestive cancer in all comparison models. Then stratified analysis showed that the increased risk was mostly contributed by gastric cancer, since significant association was observed only in gastric cancer and ORs in the sub-groups of gastric cancer were similar with those in overall analysis. It has been proposed that inflammation is a risk factor of tumorigenesis57. In the process of chronic gastric inflammation, different types of cytokines are secreted by activated neutrophils and mononuclear cells and altered cytokine levels have been observed36. Thus, it is biological plausible that IL-10 polymorphism increased risk of gastric cancer. Sub-group analysis revealed that the IL-10 -1082A>G polymorphism was only associated with gastric cancer and no association was found for other digestive cancers, indicating that the role of IL-10 varied among cancers. During sub-group analysis for ethnicities, we found ethnicity significantly affect the association between IL-10 -1082A>G polymorphism and digestive cancer risk. Since the variant -1082G allele was only associated with increased risk in Asian population and no significant association was found in Caucasian population. This ethnicity difference is common for meta-analysis and may be explained by different environmental exposure, life style, and genetic background. Of note, since the incidence of gastric cancer was higher in Asian population, most Asian studies were about gastric cancer (19 of 24 studies, as shown in table 1). The higher prevalence of gastric cancer in Asian population might be another explanation for the ethnicity difference. In the process of statistical analysis, we found the study reported by Alpizar-Alpizar W24 and colleagues was an outlier. This could be explained by ethnicity difference, since the study was conducted among Latinos. Additionally, the frequency of IL-10 -1082G allele was very low in Alpizar-Alpizar's study24. Specifically, the GG and GA genotype was not detected in cases while the GG was not detected in controls and only one participants carried the heterozygote GA genotype in controls (0% in cases and 1.14% in controls), which would led to relatively wide confidence intervals as shown in Figure 2 and Figure 3. It should also be highlighted that this study was conducted in high-risk population, which might be also related with the low frequency of G allele. In this meta-analysis, we included 40 studies with 18950 participants. The sample size was large enough to provide enough statistical power. Additionally, no publication bias was detected by Egger's test and Begg's test, suggesting our results were unbiased. On the other hand, limitation of this meta-analysis should also be also highlighted. Firstly, heterogeneity was significant in this meta-analysis. Due to the significant heterogeneity, we used random-effects model to calculate the pooled ORs, which could provide stable results. To identify the source of heterogeneity, meta-regression was conducted and revealed that sample size, HWE, source of control, and cancer types were the sources. And stratified analyses were also performed to evaluate the influence of these confounding factors. Secondly, individual data were missed and we could not assess the effects of other factors, like environmental factors, life habit, and family history. In summary, in this meta-analysis of 40 studies and 18950 participants, we found the variant IL-10 -1082G allele significantly increased susceptibility to digestive cancer, especially for gastric cancer and in Asian population.

Author Contributions

C.L., W.T. and B.L. designed this study; A.Z. and F.L. searched databases and collected full-text papers; C.L., W.T. and B.L., extracted and analyzed data; C.L., W.T., B.L., A.Z. and F.L. wrote the manuscript.
  57 in total

Review 1.  A current review of molecular mechanisms regarding osteoarthritis and pain.

Authors:  Andrew S Lee; Michael B Ellman; Dongyao Yan; Jeffrey S Kroin; Brian J Cole; Andre J van Wijnen; Hee-Jeong Im
Journal:  Gene       Date:  2013-07-02       Impact factor: 3.688

2.  Association of interleukin-1B and interleukin-1RN polymorphisms with gastric cancer in a high-risk population of Costa Rica.

Authors:  W Alpízar-Alpízar; G I Pérez-Pérez; C Une; P Cuenca; R Sierra
Journal:  Clin Exp Med       Date:  2005-12       Impact factor: 3.984

Review 3.  Role of proinflammatory cytokines in the pathophysiology of osteoarthritis.

Authors:  Mohit Kapoor; Johanne Martel-Pelletier; Daniel Lajeunesse; Jean-Pierre Pelletier; Hassan Fahmi
Journal:  Nat Rev Rheumatol       Date:  2010-11-30       Impact factor: 20.543

4.  Effect of cytokine genotypes on the hepatitis B virus-hepatocellular carcinoma association.

Authors:  Alexandra Nieters; Jian-Min Yuan; Can-Lan Sun; Zhen-Quan Zhang; Jan Stoehlmacher; Sugantha Govindarajan; Mimi C Yu
Journal:  Cancer       Date:  2005-02-15       Impact factor: 6.860

5.  The role of cytokine gene polymorphisms in colorectal cancer and their interaction with aspirin use in the northeast of Scotland.

Authors:  Mairi Macarthur; Linda Sharp; Georgina L Hold; Julian Little; Emad M El-Omar
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2005-07       Impact factor: 4.254

6.  Role of environmental and genetic factor interaction in age-related disease development: the gastric cancer paradigm.

Authors:  Giusi Irma Forte; Cinzia Calà; Letizia Scola; Antonino Crivello; Arianna Gullo; Lorenzo Marasà; Antonio Giacalone; Celestino Bonura; Calogero Caruso; Domenico Lio; Anna Giammanco
Journal:  Rejuvenation Res       Date:  2008-04       Impact factor: 4.663

Review 7.  Interleukin-10: new perspectives on an old cytokine.

Authors:  David M Mosser; Xia Zhang
Journal:  Immunol Rev       Date:  2008-12       Impact factor: 12.988

8.  Genetic determined downregulation of both type 1 and type 2 cytokine pathways might be protective against pancreatic cancer.

Authors:  Letizia Scola; Antonio Giacalone; Lorenzo Marasà; Monica Mirabile; Loredana Vaccarino; Giusi Irma Forte; Lydia Giannitrapani; Calogero Caruso; Giuseppe Montalto; Domenico Lio
Journal:  Ann N Y Acad Sci       Date:  2009-02       Impact factor: 5.691

9.  Effects of interleukin-10 polymorphisms, Helicobacter pylori infection, and smoking on the risk of noncardia gastric cancer.

Authors:  Jeongseon Kim; Young Ae Cho; Il Ju Choi; Yeon-Su Lee; Sook-Young Kim; Aesun Shin; Soo-Jeong Cho; Myeong-Cherl Kook; Ji Hyung Nam; Keun Won Ryu; Jun Ho Lee; Young-Woo Kim
Journal:  PLoS One       Date:  2012-01-03       Impact factor: 3.240

10.  Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones.

Authors:  D F Fiorentino; M W Bond; T R Mosmann
Journal:  J Exp Med       Date:  1989-12-01       Impact factor: 14.307

View more
  10 in total

1.  Role of IL-10 gene polymorphisms on the susceptibility for esophageal cancer and its association with environmental factors.

Authors:  Yingtao Yang; Xianen Fa
Journal:  Int J Clin Exp Pathol       Date:  2015-08-01

2.  Association of Interleukin-10 promotor polymorphisms with atrial fibrillation in Han Chinese.

Authors:  Dong-Dong Zheng; Shun-Nian Ji; Chu Chen; Xin-Tao Deng; Ya-Min Su; Hai-Yan Pan; Xing-Xing Cai; Xiao-Fei Li; Jian-Hua Zhu; Min Pan
Journal:  Int J Clin Exp Med       Date:  2014-11-15

3.  Interleukin-10 promotor -592A/C polymorphism is associated with slow coronary flow in Han Chinese.

Authors:  Gui-Liang Shi; Xing-Xing Cai; Ya-Min Su; Chu Chen; Xin-Tao Deng; Hai-Yan Pan; Meng-Kan Fan; Jian-Hua Zhu; Min Pan
Journal:  Int J Clin Exp Pathol       Date:  2015-04-01

4.  Single Nucleotide Polymorphisms in IL-10, IL-12p40, and IL-13 Genes and Susceptibility to Glioma.

Authors:  Haidar A Shamran; Haidar F Ghazi; Ahmed Al-Salman; Ahmad A Al-Juboory; Dennis D Taub; Robert L Price; Mitzi Nagarkatti; Prakash S Nagarkatti; Udai P Singh
Journal:  Int J Med Sci       Date:  2015-09-19       Impact factor: 3.738

Review 5.  A Causal Role of Genetically Elevated Circulating Interleukin-10 in the Development of Digestive Cancers: Evidence from Mendelian Randomization Analysis Based on 29,307 Subjects.

Authors:  Wenquan Niu; Qing Pang; Ting Lin; Zhixin Wang; Jingyao Zhang; Minghui Tai; Lingqiang Zhang; Li Zhang; Mingliang Gu; Chang Liu; Kai Qu
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.889

6.  The association of three promoter polymorphisms in interleukin-10 gene with the risk for colorectal cancer and hepatocellular carcinoma: A meta-analysis.

Authors:  Yan-Hui Shi; Dong-Mei Zhao; Yue-Fei Wang; Xue Li; Man-Ru Ji; Dan-Na Jiang; Bai-Ping Xu; Li Zhou; Chang-Zhu Lu; Bin Wang
Journal:  Sci Rep       Date:  2016-08-04       Impact factor: 4.379

7.  Protective effects of Xinji'erkang on myocardial infarction induced cardiac injury in mice.

Authors:  Juan Hu; Yong-Xue Zhang; Li Wang; Ling Ding; Guang-Yao Huang; Guo-Wei Cai; Shan Gao
Journal:  BMC Complement Altern Med       Date:  2017-06-26       Impact factor: 3.659

8.  Interleukin 10 gene rs1800896 polymorphism is associated with the risk of prostate cancer.

Authors:  Hao Chen; Jilei Tang; Nan Shen; Kewei Ren
Journal:  Oncotarget       Date:  2017-08-03

9.  Association of IL-10 gene promoter polymorphisms with susceptibility to pseudoexfoliation syndrome, pseudoexfoliative and primary open-angle glaucoma.

Authors:  Ghasem Fakhraie; Farshid Parvini; Jalaledin Ghanavi; Shima Saif; Poopak Farnia
Journal:  BMC Med Genet       Date:  2020-02-12       Impact factor: 2.103

10.  Association of IL10 gene promoter polymorphisms with risks of gastric cancer and atrophic gastritis.

Authors:  Sa Liu; Jing-Wei Liu; Li-Ping Sun; Yue-Hua Gong; Qian Xu; Jing-Jing Jing; Yuan Yuan
Journal:  J Int Med Res       Date:  2018-09-11       Impact factor: 1.671

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.